Rheumatologic symptoms in oncologic patients on PD-1 inhibitors
- 1 June 2018
- journal article
- review article
- Published by Elsevier in Seminars in Arthritis and Rheumatism
- Vol. 47 (6) , 907-910
Abstract
No abstract availableKeywords
This publication has 16 references indexed in Scilit:
- Inflammatory arthritis and sicca syndrome induced by nivolumab and ipilimumabAnnals of the Rheumatic Diseases, 2017
- Treatment of the Immune-Related Adverse Effects of Immune Checkpoint InhibitorsJAMA Oncology, 2016
- Autoimmune Arthropathy and Uveitis as Complications of Programmed Death 1 Inhibitor TreatmentArthritis & Rheumatology, 2016
- Immune-Related Adverse Events, Need for Systemic Immunosuppression, and Effects on Survival and Time to Treatment Failure in Patients With Melanoma Treated With Ipilimumab at Memorial Sloan Kettering Cancer CenterJournal of Clinical Oncology, 2015
- Toxicities of Immunotherapy for the PractitionerJournal of Clinical Oncology, 2015
- Nivolumab and Ipilimumab versus Ipilimumab in Untreated MelanomaNew England Journal of Medicine, 2015
- Arthritis and Tenosynovitis Associated With the Anti-PD1 Antibody Pembrolizumab in Metastatic MelanomaJournal of Immunotherapy, 2015
- Drug‐Associated Polymyalgia Rheumatica/Giant Cell Arteritis Occurring in Two Patients After Treatment With Ipilimumab, an Antagonist of CTLA‐4Arthritis & Rheumatology, 2014
- The blockade of immune checkpoints in cancer immunotherapyNature Reviews Cancer, 2012
- The PD‐1 pathway in tolerance and autoimmunityImmunological Reviews, 2010